 Seasoned leader with successful track record joins to help Delcath in the next phase of its development. NEW YORK, July 29, 2019 GLOBE NEWSWIRE -- Delcath Systems, Inc. OTC Pink: DCTH, an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that John R. Sylvester, a pharmaceutical and medical device executive with a greater than 30-year career focused on growing business, creating markets and implementing commercialization strategies, has joined the Delcath Board of Directors effective July 24, 2019. Mr. Sylvester currently serves as Chief Commercial Officer at BTG PLC, an international specialist healthcare company that develops and commercializes products targeting critical care, cancer and other disorders. 